NASDAQ:TCRR

Tcr2 Therapeutics Stock Forecast, Price & News

Top-Rated Stocks

$19.67

+0.12 (+0.61 %)

(As of 10/30/2020 12:00 AM ET)

Add

Compare

Today's Range

$18.87

Now: $19.67▼

$20.44

50-Day Range

$18.00

MA: $19.92▼

$22.28

52-Week Range

$5.84

Now: $19.67▼

$22.84

Volume469,098 shs

Average Volume192,938 shs

Market Capitalization$655.88 million

P/E RatioN/A

Dividend YieldN/A

Beta1.89

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. Its product candidates in pipeline comprise TC-210 mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors; TC-220 that targets MUC16 positive solid tumors; and TC-310 and TC-410 dual TRuC-T cell programs targeting CD19/22 and MSLN/MUC16, as well as TC-110 mono TRuC-T cells targeting CD19-positive B-Cell hematological malignancies. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Beat the Market (BTM) Rank^™

4.5 Analyst's Opinion

Consensus Rating
Tcr2 Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $31.80, Tcr2 Therapeutics has a forecasted upside of 61.7% from its current price of $19.67.
Amount of Analyst Coverage
Tcr2 Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.5 Community Rank

Outperform Votes
Tcr2 Therapeutics has received 93 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Tcr2 Therapeutics has received 92 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Tcr2 Therapeutics has received 50.27% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Tcr2 Therapeutics and other stocks. Vote “Outperform” if you believe TCRR will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TCRR will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Tcr2 Therapeutics does not currently pay a dividend.
Dividend Growth
Tcr2 Therapeutics does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Tcr2 Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 27.99% of the stock of Tcr2 Therapeutics is held by insiders.
Percentage Held by Institutions
45.52% of the stock of Tcr2 Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Tcr2 Therapeutics are expected to decrease in the coming year, from ($2.35) to ($2.50) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Tcr2 Therapeutics is -8.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Tcr2 Therapeutics is -8.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Tcr2 Therapeutics has a P/B Ratio of 2.94. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.60 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biological products, except diagnostic

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:TCRR

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.tcr2.com

Phone617-949-5200

Employees47

Debt

Debt-to-Equity RatioN/A

Current Ratio21.03

Quick Ratio21.03

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$6.68 per share

Price / Book2.94

Profitability

EPS (Most Recent Fiscal Year)($4.62)

Net Income$-47,600,000.00

Net MarginsN/A

Return on Equity-38.18%

Return on Assets-36.39%

Miscellaneous

Outstanding Shares33,344,000

Market Cap$655.88 million

Next Earnings Date11/10/2020 (Estimated)

OptionableNot Optionable

$19.67

+0.12 (+0.61 %)

(As of 10/30/2020 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive TCRR News and Ratings via Email

Sign-up to receive the latest news and ratings for TCRR and its competitors with MarketBeat's FREE daily newsletter.

Tcr2 Therapeutics (NASDAQ:TCRR) Frequently Asked Questions

How has Tcr2 Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Tcr2 Therapeutics' stock was trading at $8.58 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, TCRR stock has increased by 129.3% and is now trading at $19.67.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Tcr2 Therapeutics?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tcr2 Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Tcr2 Therapeutics.

When is Tcr2 Therapeutics' next earnings date?

Tcr2 Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Tcr2 Therapeutics.

How were Tcr2 Therapeutics' earnings last quarter?

Tcr2 Therapeutics Inc (NASDAQ:TCRR) released its quarterly earnings results on Wednesday, August, 12th. The company reported ($0.67) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.65) by $0.02.
View Tcr2 Therapeutics' earnings history.

What price target have analysts set for TCRR?

7 analysts have issued 1-year target prices for Tcr2 Therapeutics' shares. Their forecasts range from $25.00 to $35.00. On average, they expect Tcr2 Therapeutics' stock price to reach $31.80 in the next year. This suggests a possible upside of 61.7% from the stock's current price.
View analysts' price targets for Tcr2 Therapeutics.

Are investors shorting Tcr2 Therapeutics?

Tcr2 Therapeutics saw a decrease in short interest in the month of October. As of October 15th, there was short interest totaling 1,700,000 shares, a decrease of 19.4% from the September 30th total of 2,110,000 shares. Based on an average daily volume of 380,400 shares, the days-to-cover ratio is presently 4.5 days. Currently, 7.0% of the shares of the company are sold short.
View Tcr2 Therapeutics' Short Interest.

Who are some of Tcr2 Therapeutics' key competitors?

Some companies that are related to Tcr2 Therapeutics include SpringWorks Therapeutics (SWTX), Revolution Medicines (RVMD), Editas Medicine (EDIT), Vaxcyte (PCVX), Sorrento Therapeutics (SRNE), Forma Therapeutics (FMTX), Beam Therapeutics (BEAM), AlloVir (ALVR), Replimune Group (REPL), Bavarian Nordic A/S (BVNRY), Kymera Therapeutics (KYMR), Sangamo Therapeutics (SGMO), Cortexyme (CRTX), NanoString Technologies (NSTG) and Mesoblast (MESO).
View all competitors.

What other stocks do shareholders of Tcr2 Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tcr2 Therapeutics investors own include Editas Medicine (EDIT), Gossamer Bio (GOSS), Alector (ALEC), Kaleido Biosciences (KLDO), Precision BioSciences (DTIL), Homology Medicines (FIXX), LogicBio Therapeutics (LOGC), Sorrento Therapeutics (SRNE), Atreca (BCEL) and II-VI (IIVI).

Who are Tcr2 Therapeutics' key executives?

Tcr2 Therapeutics' management team includes the following people:

Dr. Garry E. Menzel, Pres, CEO & Director (Age 55)
Mr. Robert Hofmeister, Chief Scientific Officer (Age 52)
Dr. Alfonso Quintas Cardama M.D., Chief Medical Officer (Age 48)
Mr. Mayur Amrat Somaiya, Chief Financial Officer (Age 46)

When did Tcr2 Therapeutics IPO?

(TCRR) raised $76 million in an IPO on Thursday, February 14th 2019. The company issued 5,000,000 shares at $14.55-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow and China Renaissance were co-managers.

What is Tcr2 Therapeutics' stock symbol?

Tcr2 Therapeutics trades on the NASDAQ under the ticker symbol "TCRR."

Who are Tcr2 Therapeutics' major shareholders?

Tcr2 Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include BNP Paribas Arbitrage SA (0.02%). Company insiders that own Tcr2 Therapeutics stock include Morana Jovan-Embiricos, Neil W Gibson and Upnorth Investment Ltd.
View institutional ownership trends for Tcr2 Therapeutics.

Which major investors are buying Tcr2 Therapeutics stock?

TCRR stock was bought by a variety of institutional investors in the last quarter, including BNP Paribas Arbitrage SA. Company insiders that have bought Tcr2 Therapeutics stock in the last two years include Morana Jovan-Embiricos, and Upnorth Investment Ltd.
View insider buying and selling activity for Tcr2 Therapeutics.

How do I buy shares of Tcr2 Therapeutics?

Shares of TCRR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Tcr2 Therapeutics' stock price today?

One share of TCRR stock can currently be purchased for approximately $19.67.

How big of a company is Tcr2 Therapeutics?

Tcr2 Therapeutics has a market capitalization of $655.88 million. The company earns $-47,600,000.00 in net income (profit) each year or ($4.62) on an earnings per share basis. Tcr2 Therapeutics employs 47 workers across the globe.

What is Tcr2 Therapeutics' official website?

The official website for Tcr2 Therapeutics is www.tcr2.com.

How can I contact Tcr2 Therapeutics?

Tcr2 Therapeutics' mailing address is 100 BINNEY STREET SUITE 710, CAMBRIDGE MA, 02142. The company can be reached via phone at 617-949-5200 or via email at [email protected]

This page was last updated on 10/31/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings